BRAFV600E or closely related mutations (e.g., BRAFV600K) are found in ~50% of cutaneous melanomas and RAF/MEK therapy is the first line treatment option for BRAF‐mutant metastatic melanoma (Flaherty et al, 2012). This evidence concerns the gene MAP2K7 and cutaneous melanoma.